Benign prostatic hyperplasia: natural evolution versus medical treatment

Area of Science:

• Urology
• Epidemiology
• Geriatric Medicine

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men, with incidence increasing significantly after age 50.
• Prevalence varies across racial and ethnic groups, notably being less common in Japanese men compared to Caucasians.
• Understanding BPH epidemiology is crucial for evaluating natural progression against medical interventions.

Purpose of the Study:

• To analyze the natural evolution of benign prostatic hyperplasia (BPH) in relation to medical treatment options.
• To compare the efficacy of 'watchful waiting' versus alpha-1 blocker therapy in managing BPH symptoms.
• To highlight the importance of patient-centered decision-making regarding BPH treatment and quality of life.

Main Methods:

• Review of evidence from prospective studies, retrospective studies, and placebo arms of randomized controlled trials on BPH natural history.
• Comparative analysis of symptom progression and improvement between watchful waiting and alpha-1 blocker treatment groups.
• Consideration of patient quality of life as a factor in treatment strategy selection.

Main Results:

• The majority of BPH patients observed in natural history studies do not experience symptom worsening over time.
• Alpha-1 blocker therapy demonstrates a higher likelihood and degree of symptom improvement compared to watchful waiting.
• Both BPH symptoms and treatment modalities significantly impact patient quality of life.

Conclusions:

• Watchful waiting is a viable management option for some BPH patients due to the slow natural progression of the condition.
• Alpha-1 blockers offer superior symptomatic relief for BPH compared to non-intervention.
• Shared decision-making, incorporating patient preferences, is essential for optimizing quality of life in BPH management.